D. Boral Capital Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $30.00 price target on the stock.

Separately, HC Wainwright reiterated a "buy" rating on shares of ImmunityBio in a research report on Monday, May 5th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, ImmunityBio presently has an average rating of "Buy" and an average target price of $12.19.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $2.07 on Monday. The stock's 50-day moving average is $2.68 and its two-hundred day moving average is $3.38. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -2.25 and a beta of 0.33. ImmunityBio has a 1 year low of $1.83 and a 1 year high of $9.16.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). As a group, research analysts predict that ImmunityBio will post -0.92 EPS for the current year.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in ImmunityBio by 2.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,302,083 shares of the company's stock valued at $3,919,000 after acquiring an additional 25,410 shares during the period. Vanguard Group Inc. grew its position in ImmunityBio by 17.4% during the first quarter. Vanguard Group Inc. now owns 20,344,554 shares of the company's stock valued at $61,237,000 after acquiring an additional 3,016,325 shares during the period. XTX Topco Ltd grew its position in ImmunityBio by 5.4% during the first quarter. XTX Topco Ltd now owns 111,647 shares of the company's stock valued at $336,000 after acquiring an additional 5,764 shares during the period. Meeder Advisory Services Inc. purchased a new stake in shares of ImmunityBio in the first quarter worth about $48,000. Finally, Dauntless Investment Group LLC purchased a new stake in shares of ImmunityBio in the first quarter worth about $283,000. Hedge funds and other institutional investors own 8.58% of the company's stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.